Awe superviser ronen and can you please read item number one . Is an ordinance to the amend the administrative code to allow tenants who have received a passthrough relief from the landlords from the rent board from financial hardship. Superviser ronen i am wondering if supervisor peskin will join us. I dont see anyone from his office. I will open this up to Public Comment first and get someone from his office here. If there is any member of the public would like to speak on this item, please come forward now. Good morning. Teresa from senior disability and action. I am so thrilled that mr. Peskin, supervisor peskin, has put this forth. This is going to be so important to so many. And the building Affordable Housing and have people priced out because of passthrough is not a good thing. Thank you so much. I do hope you will support this with all of your energy and hearts and souls. Lets get this through. Thank you. Jordan davis speaking for myself. I stand up for rent relief no matter w
Manus welcome to i am manus cranny. Welcome to the pulse. I am manus cranny. The story of day from the asia. The president of toshiba along with two other executives, their resignation and their formal News Conference and this was a 1. 2 billion scandal restating their earnings over the past six years, unrealistic led to what is a systemic flawed accounting process, challenging the culture within japan. Probably one of the single most important issues that will be addressed here which is so much power for people as of the top and no way for anybody to really challenge the toshiba accounting methods. Everything from Nuclear Reactors and ships. A is now falling on hisao tanaka the president. If we have any headlines, we will bring them to you. Our top story and that is commodities. Bloomberg commodities index dropped to a 13 year low yesterday. Right . Ryan you have to go back to 2002 to see Commodity Prices where they are now. A fiveyear low. 2012 when we had the darkest days of the eur
The novel agent targets CD40 ligand and showed promising results in a two-stage, phase 2 clinical trial, particularly for patients with notable symptom burden but limited systemic organ involvement.